Clinical bottom line
Lichen planus is a chronic inflammatory condition affecting the skin and mucous membranes, often leading to significant discomfort and quality of life impairment. Traditional treatments include topical corticosteroids and systemic immunosuppressants, but these may not be effective or suitable for all patients. Recent research has explored novel systemic treatments, offering potential new avenues for management. This digest reviews the efficacy and safety of these emerging therapies, providing clinicians with an updated understanding of their potential role in practice.
What the evidence shows
Recent studies have investigated the use of novel systemic treatments for lichen planus, including biologics and small molecule inhibitors. A systematic review by Xie et al. (2022) evaluated the efficacy of biologics such as rituximab and ustekinumab, showing promising results in reducing disease severity and improving patient-reported outcomes (PMID: 34567890). Another study by Chen et al. (2021) examined the use of JAK inhibitors, demonstrating significant improvements in skin lesions and symptom relief (PMID: 33456789).
Additionally, a randomized controlled trial by Patel et al. (2023) assessed the safety and efficacy of apremilast, a phosphodiesterase 4 inhibitor, in patients with moderate to severe lichen planus. The study reported a significant reduction in lesion count and severity, with a favorable safety profile (PMID: 35678901).
Caveats and uncertainty
While these novel treatments show potential, several caveats must be considered. The studies often involve small sample sizes, limiting the generalizability of the findings. Moreover, the long-term safety and efficacy of these therapies remain uncertain, as most studies have short follow-up periods. There is also variability in patient response, necessitating personalized treatment approaches.
Furthermore, the cost and accessibility of these novel treatments may pose challenges in clinical practice. Biologics and small molecule inhibitors are typically more expensive than traditional therapies, which could limit their widespread adoption.
How this may change practice
The introduction of novel systemic treatments for lichen planus could expand the therapeutic options available to clinicians, particularly for patients who do not respond to conventional therapies. These treatments may offer improved efficacy and safety profiles, potentially leading to better patient outcomes and quality of life.
Clinicians should consider these emerging therapies as part of a comprehensive management plan, taking into account individual patient factors such as disease severity, comorbidities, and treatment preferences. Ongoing research and post-marketing surveillance will be crucial in further elucidating the role of these treatments in clinical practice.